Expert Financial Analysis and Reporting

Recent Reports

• Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02 (0)

Recent Blogs

• Novartis Releases Three Month Interim Data for JULIET Trial of CTL-019 in r/r DLBCL (0)
• Alimera Sciences: Company Achieves Breakeven Pretax Cash Flow in 2Q, 2017 Despite Slow Unit Demand for Iluvien (ALIM, Buy, $1.50) (0)
• FDA Announces July 12 AdCom Meeting for CTL-019: Thoughts on How This Might Affect Investor Perceptions of Kite (KITE, Underperform, $80.25) and Cryoport (CYRX, Buy, $3.89) (0)
• Cryoport: As Its Clients Transition from Clinical Development to Commercial, Growth Could Be Explosive (CYRX, $6.89, Buy) (0)
• Northwest Biotheraputics to Make Presentation at ASCO Today Monday June 5, 2017 (0)
• Portola Pharmaceuticals: AndexXa BLA Resubmitted; Reiterating Buy (PTLA, $61.41, Buy) (0)
• Key Investment Considerations Relating to Much Anticipated CAR-T Product Launches By Kite and Novartis Later This Year (0)
• Cytokinetics: Reiteration of My Long Standing Buy Recommendation Based on an Extraordinary Pipeline (CYTK, $12.90, Buy) (0)
• Cytokinetics: Comments on the Upside Move Today (CYTK, Buy, $12.90) (0)
• Cryoport: Upping 2020 Price Target from $14.50 to $20.00 (CYRX, Buy, $6.89) (0)
• SmithOnStocks Top Stock Picks for 2017, January 3, 2017 (0)

Social Feeds

• • $ATRS Reiterating long standing buy in this new report https://t.co/MYahKsLT1M, Aug 17
  • $ALIM Company Achieves Breakeven Pretax Cash Flow in 2Q 07 Despite Slow Unit Demand for Iluvien (ALIM, Buy, $1.50) https://t.co/dzfKiDLgRO, Aug 14
  • $cyrx New report:: As Its Clients Transition from Clinical Development to Commercial; Growth Could Be Explosive https://t.co/HuwjvvE9ol, Aug 10
  • $PTLA AndexXa BLA Resubmitted; Reiterating Buy https://t.co/ZQMCktCvbN, Aug 09
  • $CYTK Reiteration of My Long Standing Buy Recommendation Based on an Extraordinary Pipeline https://t.co/oMIt3DbP2z, Aug 09